GlucoTrack FY26 Q2 net loss narrows 19.8% to USD 3.81 million

• GlucoTrack posted a GAAP net loss of USD 3.81 million for the quarter ended June 30, 2026, narrowing from USD 4.76 million.
• R&D expense fell to USD 2.02 million from USD 3.15 million, due to lower accrued product and manufacturing costs for the CBGM model.
• G&A costs declined to USD 1.38 million from USD 1.65 million, on lower professional fees and personnel costs.
• Cash and cash equivalents dropped to USD 1.12 million at June 30, 2026 from USD 7.38 million at Dec. 31, 2025; accumulated deficit totaled USD 159.99 million.
• Submitted an FDA IDE application in May 2026 for a U.S. CBGM clinical study; closed an Australia long-term feasibility study following a reassessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038317), on August 14, 2026, and is solely responsible for the information contained therein.